High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: Effects of valsartan and simvastatin

American Journal of Nephrology

Volumn 30, Issue 2, 2009, Pages 99-111

  Naito, Masayo ^a   Shenoy, Ananth ^c   Aoyama, Isao ^a   Koopmeiners, Joseph S ^b   Komers, Radko ^c   Schnaper, H William ^d   Bomsztyk, Karol ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angiotensin II; Glomerular mesangial cell; Hyperglycemia; Proinflammatory action

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ACTIN; CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; DNA; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; TRANSCRIPTION FACTOR FRA 1; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INFLAMMATION; KIDNEY INJURY; MESANGIUM CELL; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA EXTRACTION; RNA PROCESSING;

ANGIOTENSIN II; GENE EXPRESSION REGULATION; GLUCOSE; HEMODYNAMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; INFLAMMATION; KIDNEY; MESANGIAL CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN; TETRAZOLES; VALINE;

EID: 60449091135     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000203619     Document Type: Article

References (106)

1. Salzet M, Wattez C, Baert JL, Malecha J: Biochemical evidence of angiotensin II-like peptides and proteins in the brain of the rhynchobdellid leech Theromyzon tessulatum. Brain Res 1993; 631: 247-255. (Pubitemid 24009995)
2. Salzet M, Deloffre L, Breton C, Vieau D, Schoofs L: The angiotensin system elements in invertebrates. Brain Res Brain Res Rev 2001; 36: 35-45.
3. Salzet M, Verger-Bocquet M: Elements of angiotensin system are involved in leeches and mollusks immune response modulation. Brain Res Mol Brain Res 2001; 94: 137-147. (Pubitemid 32964755)
4. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A: Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21: 20-27. (Pubitemid 44921816)
5. Fliser D, Buchholz K, Haller H: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107. (Pubitemid 39319009)
6. Dagenais NJ, Jamali F: Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 2005; 25: 1213-1229.
7. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R: Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007; 18: 1093-1102. (Pubitemid 46536895)
8. Theuer J, Dechend R, Muller DN, Park JK, Fiebeler A, Barta P, Ganten D, Haller H, Dietz R, Luft FC: Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord 2002; 2: 3. (Pubitemid 38824807)
9. Jaimes EA, Tian RX, Pearse D, Raij L: Upregulation of glomerular COX-2 by angiotensin II: role of reactive oxygen species. Kidney Int 2005; 68: 2143-2153. (Pubitemid 43117788)
10. Chen YW, Liu F, Tran S, Zhu Y, Hebert MJ, Ingelfinger JR, Zhang SL: Reactive oxygen species and nuclear factor-kappa B pathway mediate high glucose-induced Pax-2 gene expression in mouse embryonic mesenchymal epithelial cells and kidney explants. Kidney Int 2006; 70: 1607-1615. (Pubitemid 44606996)
11. 1 receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. J Hypertens 2002; 20: 1157-1163.
12. Xoriuchi M, Hamai M, Cui TX, Iwai M, Minokoshi Y: Cross talk between angiotensin II type 1 and type 2 receptors: cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition. Hypertens Res 1999; 22: 67-74. (Pubitemid 29371678)
13. Li XC, Carretero OA, Zhuo JL: Cross-talk between angiotensin II and glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1/2 in rat glomerular mesangial cells. Biochem Pharmacol 2006; 71: 1711-1719.
14. Abrass CK, Berfield AK, Ryan MC, Carter WG, Hansen KM: Abnormal development of glomerular endothelial and mesangial cells in mice with targeted disruption of the lama3 gene. Kidney Int 2006; 70: 1062-1071.
15. Lee FT, Cao Z, Long DM, Panagiotopoulos S, Jerums G, Cooper ME, Forbes JM: Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 2004; 15: 2139-2151. (Pubitemid 39031352)
16. Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J: Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 2006; 21: 16-20. (Pubitemid 43057101)
17. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J: Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86: 1266-1272.
18. Dalla Vestra M, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, Plebani M, Fioretto P: Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16(suppl 1):S78-S82. (Pubitemid 41725090)
19. Phillips A, Janssen U, Floege J: Progression of diabetic nephropathy. Insights from cell culture studies and animal models. Kidney Blood Press Res 1999; 22: 81-97.
20. Abrass CK, Spicer D, Raugi GJ: Induction of nodular sclerosis by insulin in rat mesangial cells in vitro: studies of collagen. Kidney Int 1995; 47: 25-37.
21. Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56: 393-405. (Pubitemid 29353136)
22. Coughlan MT, Forbes JM, Cooper ME: Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl 2007;(106):S54-S60.
23. Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, Marrero MB: Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 2002; 61: 1605-1616. (Pubitemid 34437914)
24. Lansang MC, Price DA, Laffel LM, Osei SY, Fisher ND, Erani D, Hollenberg NK: Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001; 59: 1432-1438. (Pubitemid 32281232)
25. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB: Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002; 13: 894-902. (Pubitemid 34274085)
26. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC: Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290:F762-F768. (Pubitemid 43724932)
27. LIPID: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
28. Brown MS, Goldstein JL: Atherosclerosis. Scavenging for receptors. Nature 1990; 343: 508-509.
29. Heusinger-Ribeiro J, Fischer B, Goppelt-Struebe M: Differential effects of simvastatin on mesangial cells. Kidney Int 2004; 66: 187-195. (Pubitemid 38870094)
30. Greenwood J, Mason JC: Statins and the vascular endothelial inflammatory response. Trends Immunol 2007; 28: 88-98. (Pubitemid 46178495)
31. Sander GE, Giles TD: Diabetes mellitus and heart failure. Am Heart Hosp J 2003; 1: 273-280.
32. Kim SI, Kim HJ, Han DC, Lee HB: Effect of lovastatin on small GTP binding proteins and on TGF-beta1 and fibronectin expression. Kidney Int Suppl 2000; 77:S88-S92.
33. Kim SI, Han DC, Lee HB: Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000; 11: 80-87. (Pubitemid 30020429)
34. Dechend R, Fiebler A, Lindschau C, Bischoff H, Muller D, Park JK, Dietz R, Haller H, Luft FC: Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens 2001; 14: 55S-61S. (Pubitemid 32506697)
35. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, et al: Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3methylglutaryl coenzyme a reductase inhibitor. Circulation 2001; 104: 576-581. (Pubitemid 32738128)
36. Dechen R, Muller D, Park JK, Fiebeler A, Haller H, Luft FC: Statins and angiotensin II-induced vascular injury. Nephrol Dial Transplant 2002; 17: 349-353. (Pubitemid 34211124)
37. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, et al: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000; 58: 1420-1430. (Pubitemid 30739648)
38. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002;(82):S12-S22. (Pubitemid 35356990)
39. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J: Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998; 161: 430-439. (Pubitemid 28285552)
40. Awad AS, Webb RL, Carey RM, Siragy HM: Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats. Am J Hypertens 2005; 18: 544-548. (Pubitemid 40502928)
41. Siragy HM, Howell NL, Ragsdale NV, Carey RM: Renal interstitial fluid angiotensin. Modulation by anesthesia, epinephrine, sodium depletion, and renin inhibition. Hypertension 1995; 25: 1021-1024.
42. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002; 39: 129-134. (Pubitemid 34098101)
43. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H: Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002; 39: 316-322.
44. Zeng L, Xu H, Chew TL, Chisholm R, Sadeghi MM, Kanwar YS, Danesh FR: Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27. J Am Soc Nephrol 2004; 15: 1711-1720. (Pubitemid 38822049)
45. Takeuchi Y, Yamauchi K, Nakamura J, Shigematsu S, Hashizume K: Angiotensin II regulates migration in mouse cultured mesangial cells: evidence for the presence of receptor subtype-specific regulation. J Endocrinol 2006; 191: 361-367. (Pubitemid 44830611)
46. Kacharmina JE, Crino PB, Eberwine J: Preparation of cDNA from single cells and subcellular regions. Methods Enzymol 1999; 303: 3-18. (Pubitemid 29246248)
47. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W: Applied Linear Statistical Models. Boston, WCB/McGraw-Hill, 1996.
48. Hisada Y, Sugaya T, Yamanouchi M, Uchida H, Fujimura H, Sakurai H, Fukamizu A, Murakami K: Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 1999; 103: 627-635. (Pubitemid 29122415)
49. Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, Takahashi T, Makino S, Kato T, Ogawa S: Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 2000; 275: 29717-29723. (Pubitemid 32043853)
50. Campos AH, Zhao Y, Pollman MJ, Gibbons GH: DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res 2003; 92: 111-118. (Pubitemid 36105614)
51. Romero DG, Rilli S, Plonczynski MW, Yanes LL, Zhou MY, Gomez-Sanchez EP, Gomez-Sanchez CE: Adrenal transcription regulatory genes modulated by angiotensin II and their role in steroidogenesis. Physiol Genomics 2007; 30: 26-34. (Pubitemid 47173286)
52. Chang LT, Sun CK, Chiang CH, Wu CJ, Chua S, Yip HK: Impact of simvastatin and losartan on antiinflammatory effect: in vitro study. J Cardiovasc Pharmacol 2007; 49: 20-26. (Pubitemid 46184327)
53. Ni W, Kitamoto S, Ishibashi M, Usui M, Inoue S, Hiasa K, Zhao Q, Nishida K, Takeshita A, Egashira K: Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004; 24: 534-539. (Pubitemid 38326149)
54. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J: Effects of angiotensin II receptor blockade with valsartan on proinflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46: 735-739. (Pubitemid 44378243)
55. Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, Endoh M, Nomoto Y, Sakai H: In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 1995; 44: 1233-1238.
56. Floege J, Burg M, Hugo C, Gordon KL, Van Goor H, Reidy M, Couser WG, Koch KM, Johnson RJ: Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 1998; 9: 792-801. (Pubitemid 28209088)
57. Floege J, Eng E, Lindner V, Alpers CE, Young BA, Reidy MA, Johnson RJ: Rat glomerular mesangial cells synthesize basic fibroblast growth factor. Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. J Clin Invest 1992; 90: 2362-2369. (Pubitemid 23010054)
58. Morey JS, Ryan JC, Van Dolah FM: Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. Biol Proced Online 2006; 8: 175-193.
59. Shanmugam N, Gaw Gonzalo IT, Natarajan R: Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes 2004; 53: 795-802. (Pubitemid 38270651)
60. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S: Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001; 107: 889-898. (Pubitemid 32274042)
61. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC: Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002; 62: 929-939.
62. Mohn KL, Laz TM, Melby AE, Taub R: Immediate-early gene expression differs between regenerating liver, insulin-stimulated H-35 cells, and mitogen-stimulated Balb/c 3T3 cells. Liver-specific induction patterns of gene 33, phosphoenolpyruvate carboxykinase, and the jun, fos, and egr families. J Biol Chem 1990; 265: 21914-21921.
63. Adiseshaiah P, Peddakama S, Zhang Q, Kalvakolanu DV, Reddy SP: Mitogen regulated induction of FRA-1 proto-oncogene is controlled by the transcription factors binding to both serum and TPA response elements. Oncogene 2005; 24: 4193-4205. (Pubitemid 40961774)
64. Kreisberg JI, Radnik RA, Ayo SH, Garoni J, Saikumar P: High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell culture. Kidney Int 1994; 46: 105-112. (Pubitemid 2105719)
65. Ingram AJ, Scholey JW: Protooncogene expression and diabetic kidney injury. Kidney Int Suppl 1997; 60:S70-S76.
66. Schnaper HW, Hayashida T, Poncelet AC: It's a Smad world: regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol 2002; 13: 1126-1128. (Pubitemid 34274113)
67. Choi ME: Mechanism of transforming growth factor-beta1 signaling. Kidney Int Suppl 2000; 77:S53-S58.
68. Border WA, Noble NA, Ketteler M: TGF-β: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. Kidney Int Suppl 1995; 49:S59-S61.
69. Kumar R, Lutz W, Frank E, Im HJ: Immediate early gene X-1 interacts with proteins that modulate apoptosis. Biochem Biophys Res Commun 2004; 323: 1293-1298. (Pubitemid 39296565)
70. Jhun BH, Haruta T, Meinkoth JL, Leitner W, Draznin B, Saltiel AR, Pang L, Sasaoka T, Olefsky JM: Signal transduction pathways leading to insulin-induced early gene induction. Biochemistry 1995; 34: 7996-8004.
71. Rupprecht HD, Dann P, Sukhatme VP, Sterzel RB, Coleman, DL: Effect of vasoactive agents on induction of Egr-1 in rat mesangial cells: correlation with mitogenicity. Am J Physiol 1992; 263:F623-F636.
72. Eto K, Kaur V, Thomas MK: Regulation of insulin gene transcription by the immediate-early growth response gene Egr-1. Endocrinology 2006; 147: 2923-2935. (Pubitemid 43764628)
73. Solow BT, Derrien A, Smith JA, Jarett L, Harada S: Angiotensin II inhibits insulin-induced egr-1 expression in mesangial cells. Arch Biochem Biophys 1999; 370: 308-313. (Pubitemid 29491439)
74. Gousseva N, Kugathasan K, Chesterman CN, Khachigian LM: Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. J Cell Biochem 2001; 81: 523-534. (Pubitemid 32405770)
75. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581-588. (Pubitemid 44209181)
76. Volpe M, Ruilope LM, McInnes GT, Waeber B, Weber MA: Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005; 19: 331-339.
77. Leehey DJ, Isreb MA, Marcic S, Singh AK, Singh R: Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II. Nephron Exp Nephrol 2005; 100:e46-e53. (Pubitemid 40674605)
78. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, Mundel P, Chen S: Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002; 62: 901-913. (Pubitemid 35316719)
79. Nahman NS Jr, Leonhart KL, Cosio FG, Hebert CL: Effects of high glucose on cellular proliferation and fibronectin production by cultured human mesangial cells. Kidney Int 1992; 41: 396-402.
80. Wilmer WA, Dixon CL, Hebert C: Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int 2001; 60: 858-871.
81. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999; 274: 5830-5834. (Pubitemid 29109239)
82. Clarkson MR, Murphy M, Gupta S, Lambe T, Mackenzie HS, Godson C, Martin F, Brady HR: High glucose-altered gene expression in mesangial cells. Actin-regulatory protein gene expression is triggered by oxidative stress and cytoskeletal disassembly. J Biol Chem 2002; 277: 9707-9712. (Pubitemid 34968071)
83. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE: Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53: 2079-2086. (Pubitemid 38970758)
84. Lappin DW, Doran P, Godson C, Brady HR: Gene responses to hyperglycaemia. Exp Nephrol 2002; 10: 120-129.
85. Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071. (Pubitemid 27163860)
86. Tak PP, Firestein GS: NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
87. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R: Hyperglycemia- induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999; 48: 855-864. (Pubitemid 29153087)
88. Touyz RM, Tabet F, Schiffrin EL: Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 2003; 30: 860-866. (Pubitemid 37506154)
89. Yu HY, Inoguchi T, Nakayama M, Tsubouchi H, Sato N, Sonoda N, Sasaki S, Kobayashi K, Nawata H: Statin attenuates high glucose-induced and angiotensin II-induced MAP kinase activity through inhibition of NAD(P)H oxidase activity in cultured mesangial cells. Med Chem 2005; 1: 461-466.
90. Shaw S, Wang X, Redd H, Alexander GD, Isales CM, Marrero MB: High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. J Biol Chem 2003; 278: 30634-30641. (Pubitemid 36994568)
91. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS: Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997; 272: 601-608.
92. Hasan RN, Schafer AI: Hemin upregulates Egr-1 expression in vascular smooth muscle cells via reactive oxygen species ERK-1/2-Elk-1 and NF-kappaB. Circ Res 2008; 102: 42-50.
93. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, Chiao PJ: NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004; 24: 7806-7819. (Pubitemid 39121503)
94. Amiri F, Garcia R: Regulation of angiotensin II receptors and PKC isoforms by glucose in rat mesangial cells. Am J Physiol 1999; 276: F691-F699. (Pubitemid 29249688)
95. Tsiani E, Lekas P, Fantus IG, Dlugosz J, Whiteside C: High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am J Physiol Endocrinol Metab 2002; 282: E161-E169.
96. Tsubouchi H, Inoguchi T, Sonta T, Sato N, Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H: Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 2005; 39: 444-452. (Pubitemid 41021643)
97. Yoshimura A, Inui K, Nemoto T, Uda S, Sugenoya Y, Watanabe S, Yokota N, Taira T, Iwasaki S, Ideura T: Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 1998; 9: 2027-2039. (Pubitemid 28482150)
98. Hattori M, Nikolic-Paterson DJ, Miyazaki K, Isbel NM, Lan HY, Atkins RC, Kawaguchi H, Ito K: Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int Suppl 1999; 71:S47-S50. (Pubitemid 29304812)
99. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR: Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57: 714-723.
100. Yoshimura A, Nemoto T, Sugenoya Y, Inui K, Watanabe S, Inoue Y, Sharif S, Yokota N, Uda S, Morita H, et al: Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Kidney Int Suppl 1999; 71:S84-S87. (Pubitemid 29304821)
101. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, Takeshita A: Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001; 89: 415-421. (Pubitemid 34132657)
102. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui M, Kaibuchi K, Shimokawa H, et al: Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002; 39: 245-250. (Pubitemid 34165223)
103. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D, et al: Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007; 100: 1442-1451. (Pubitemid 46834756)
104. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G: Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002; 61: 1635-1645. (Pubitemid 34437917)
105. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13: 2898-2908. (Pubitemid 35386909)
106. Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME, Cao Z: Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 2003; 64: 565-571. (Pubitemid 36871927)